AR and prostate cancer: Regarding advanced forms of PCa, even castration-resistant ones, the significant effects of BETis have been attributed to AR activity and signaling, with initial preclinical studies finding them less effective in AR-null versus AR-positive prostate cancer [17,20,21,22].